Why is low-dose Aspirin suddenly an enemy of Big Pharma?
Like clockwork, two of the world’s largest propaganda machines, mainstream media’s CNN and New York Times, quickly pounced in to feign and fabricate news against two major studies that prove low- dose aspirin helps COVID-19 patients.
Separate research at the George Washington University and Israel’s Barzilai Medical Center indicate inexpensive over-the-counter aspirin can protect the lungs of China Virus COVID patients. It also minimizes the need for mechanical ventilation.
The George Washington University team investigated over 400 COVID patients from hospitals across the United States who take aspirin unrelated to their COVID disease.
They learned that the treatment reduced the risk of several parameters by almost half: reducing mechanical ventilation by 44%, ICU admissions by 43%, and overall in-hospital mortality by 47%.
Predictably, just as they’ve done with other far less costly and effective treatments, mainstream media began countering for the leftist pharmaceutical industry and politically socialist agendas.
“As we learned about the connection between blood clots and COVID-19, we knew that aspirin – used to prevent stroke and heart attack – could be important for COVID-19 patients,” Dr. Jonathan Chow of the GWU study team, announced.
“Our research found an association between low-dose aspirin and decreased severity of COVID-19 and death,” he stated.
Counter to the NY Times and CNN reactions, low-dose aspirin has been an established and proven common treatment for anyone suffering from blood clotting issues or in danger of stroke. This includes most people who had a heart attack or a myocardial infarction.
Although affecting the respiratory system, the coronavirus has been associated with small blood vessel clotting, causing tiny blockages in the pulmonary blood system, leading to ARDS – acute respiratory distress syndrome.
Deaths and injuries from the experimental “vaccines” have also been attributed to clotting, heart inflammation and other concerns that may be treated with low-dose aspirin.
In Israel, researchers at Barzilai Medical Center experienced similar results in their studies last March. In addition to its effect on blood clots, they found that aspirin carried immunological benefits and that the group taking it was 29% less likely to become infected with the virus in the first place.
“Aspirin is low cost, easily accessible and millions are already using it to treat their health conditions,” Chow indicated. “Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.”
Even the Harvard Health Medical School states “taking low-dose aspirin for ‘secondary prevention’ is not controversial. Secondary prevention is for people who already have had a heart attack, certain kinds of strokes, or other diagnosed cardiovascular disease that puts them at high risk of additional problems.”
“If somebody already has evidence of cardiovascular disease, there’s no question they should be on an aspirin unless they have some major bleeding issues or an allergy that prevents them from taking aspirin,” Dr. Deepak Bhatt of Harvard concluded.
Please Support These Quality American Family Owned Businesses